CLDX — Celldex Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $2.45bn
- $2.02bn
- $6.88m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.57 | 7.42 | 4.65 | 2.36 | 6.88 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 58.6 | 70.8 | 75.9 | 118 | 161 |
Operating Profit | -55 | -63.4 | -71.2 | -115 | -155 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -50.9 | -60.9 | -70.7 | -112 | -141 |
Provision for Income Taxes | |||||
Net Income After Taxes | -50.9 | -59.8 | -70.5 | -112 | -141 |
Net Income Before Extraordinary Items | |||||
Net Income | -50.9 | -59.8 | -70.5 | -112 | -141 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -50.9 | -59.8 | -70.5 | -112 | -141 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.38 | -1.62 | -1.59 | -2.08 | -2.66 |